US 12,168,017 B2
D2O stabilized pharmaceutical formulations
Gregory I. Ostrow, San Diego, CA (US); Kenneth J. Widder, Rancho Santa Fe, CA (US); and David S. Baker, Carlsbad, CA (US)
Assigned to SYDNEXIS, INC., Del Mar, CA (US)
Filed by Sydnexis, Inc., Del Mar, CO (US)
Filed on Jun. 1, 2021, as Appl. No. 17/335,490.
Application 17/335,490 is a continuation of application No. 16/805,612, filed on Feb. 28, 2020, granted, now 11,052,095.
Application 16/805,612 is a continuation of application No. 15/578,202, granted, now 11,052,094, previously published as PCT/US2016/034823, filed on May 27, 2016.
Claims priority of provisional application 62/168,538, filed on May 29, 2015.
Prior Publication US 2021/0283142 A1, Sep. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5575 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/08 (2006.01); A61K 31/18 (2006.01); A61K 31/216 (2006.01); A61K 31/565 (2006.01); A61K 31/57 (2006.01); A61K 47/02 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/5575 (2013.01) [A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 31/18 (2013.01); A61K 31/216 (2013.01); A61K 31/565 (2013.01); A61K 31/57 (2013.01); A61K 47/02 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01); A61P 27/02 (2018.01)] 20 Claims
 
1. A method of treating an ophthalmic condition or disease comprising administering an ophthalmic composition to a subject in need thereof, the ophthalmic composition comprising:
(i) about 0.015 wt % to about 1 wt % pilocarpine or a pharmaceutically acceptable salt of pilocarpine, and
ii deuterated water, wherein the ophthalmic composition comprises at least 95% deuterated water;
wherein the composition comprises a pD of about 4 to about 8; wherein the composition comprises at least about 80% pilocarpine based on initial concentration after at least about one week under storage conditions.